BUZZ-Lucid Diagnostics slides on $25 mln stock sale

Reuters09-10
BUZZ-<a href="https://laohu8.com/S/LUCD">Lucid Diagnostics</a> slides on $25 mln stock sale

** Shares of Lucid Diagnostics LUCD.O down 18.1% at $1.04 premarket after $25 mln follow-on prices

** New York City-based cancer prevention firm announces selling 25 mln shares at $1

** Offering price represents ~21% discount to stock's last close

** The PAVmed Inc PAVM.O subsidiary plans to use net proceeds for working capital, general purposes

** Canaccord Genuity and BTIG are joint bookrunners for the offering

** Lucid has ~108.5 mln shares outstanding for $138 mln market cap

** Its flagship product, the EsoGuard Esophageal DNA Test, is used to screen for esophageal precancer and cancer in at-risk gastroesophageal reflux disease patients

** Through Tues, shares gained 55% YTD

** All 6 analysts are bullish on LUCD and median PT is $3, per LSEG

(Lance Tupper is a Reuters market analyst. The views expressed are his own)

((lance.tupper@tr.com 1-646-279-6380))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment